Here, we explored a new therapeutic strategy for HCC by testing the effectiveness of three selected 4,11-diaminoanthra[2,3-b]furan-5,10-diones (compounds 1–3) on p53 wild-type HepG2 and p53-deficient Hep3B cancer cell lines. Here, TP53 is linked to hepatocellular carcinoma.